ReviewClinical reviews in allergy & immunology2023
Renal Disease and Systemic Sclerosis: an Update on Scleroderma Renal Crisis.
Review in Clinical reviews in allergy & immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 77 citations in OpenAlex.
- Inflammatory and total immunoglobulin biomarker domains in systemic sclerosis vasculopathy: a phenotype-based cross-sectional study.Clinical rheumatology · 2026Article
- Navigating evidence-based recommendations for the management of systemic sclerosis.Nature reviews. Rheumatology · 2026Review
- Phosphodiesterase-5 inhibitors, but not calcium channel blockers, improve peripheral vascular function in systemic sclerosis.Clinical and experimental rheumatology · 2026Article
- Gain of function NOTCH4 variants disrupt angiogenesis in systemic sclerosis.Annals of the rheumatic diseases · 2026Article
- Clinical and psychosocial determinants of oral handicap in systemic sclerosis: a cross-sectional study.Rheumatology international · 2026Article
- Increased thyroid stiffness without volume change in systemic sclerosis: a case-control study using two-dimensional shear wave elastography.Rheumatology international · 2026Article
- Cardiac involvement in systemic sclerosis: mechanisms, manifestations and management.Rheumatology (Oxford, England) · 2026Review
- Distinct Effects of Complement C4A and C4B Copy Numbers in Systemic Sclerosis Serological and Clinical Subtypes.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Close association of kinesiophobia with physical performance in patients with systemic sclerosis.Rheumatology international · 2026Article
- Scleroderma Renal Crisis and Posterior Reversible Encephalopathy Syndrome Triggered by Non-steroidal Anti-inflammatory Drugs.Internal medicine (Tokyo, Japan) · 2026Article
- Emergency in pediatric rheumatology: a narrative review.Frontiers in medicine · 2026Review
- The Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025).Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- Navigating the Unknown: Scleroderma Renal Crisis and a Fatal Cardiac Complication in a Young Patient With MCTD With Coexisting Anti-U3 RNP and Anti-RNA Polymerase III Antibodies.Case reports in rheumatology · 2026Article
- From Silicosis to Systemic Sclerosis: Erasmus Syndrome in a Young Galamseyer-Case Report.Case reports in dermatological medicine · 2026Article
- Treating skin involvement in diffuse cutaneous systemic sclerosis: results from an international scleroderma specialist survey.Rheumatology advances in practice · 2026Article
- Tissue-specific oxidative stress and bleomycin hydrolase signatures are associated with organ-specific fibrotic responses in a mouse model of systemic sclerosis.Frontiers in cell and developmental biology · 2026Article
- Clinical characteristics and treatment patterns of systemic sclerosis patients in China: a single-center retrospective study.Clinical and experimental medicine · 2025Observational
- [S2k guidelines on diagnostics and treatment of systemic sclerosis : Full version].Zeitschrift fur Rheumatologie · 2025Review
- [S2k guidelines on diagnostics and treatment of systemic sclerosis : Abridged version].Zeitschrift fur Rheumatologie · 2025Review
- Fast and robust invariant generalized linear models.Journal of computational and graphical statistics : a joint publication of American Statistical Association, Institute of Mathematical Statistics, Interface Foundation of North America · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis (SSc) with a mortality of 20% at 6 months. Once the leading cause of mortality in scleroderma (SSc), it remains a serious complication, often necessitating level three care for patients affected. Whilst renal outcomes have significantly improved following the advent of angiotensin-converting enzyme inhibitor (ACEi) therapy, SRC remains a precarious challenge for clinicians, due to lack of preventative measures and the fact that patients can rapidly decline despite best medical management. Large cohort studies spanning decades have allowed clear identification of phenotypes particularly at risk of developing SRC thus allowing enhanced monitoring and early identification in those individuals. Novel urinary biomarkers for renal disease in SSc may offer a new window for early identification of SRC patients and response to treatment. Multiple studies have demonstrated increased activity of complement pathways in SRC with some anecdotal cases exhibiting serological response to treatment with eculizumab where ACEi and therapeutic plasma exchange (TPE) were not successful. Endothelin-1 blockade, a therapeutic strategy in other SSc vasculopathies, has shown potential as a target but clinical trials are yet to show a clear treatment benefit. Clear guidelines for the management of SRC are in place to standardise care and facilitate early collaboration between rheumatology and renal physicians. Outcomes following renal transplant have improved but the mortality of SRC remains high, indicating the need for continued exploration of the mechanisms precipitating and exacerbating SRC in order to develop novel therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.